Ertugliflozin and Sitagliptin Co-initiation in Patients with Type 2 Diabetes: The VERTIS SITA Randomized Study

[1]  J. Rosenstock,et al.  Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET) , 2018, Diabetes, obesity & metabolism.

[2]  R. Guthrie.  Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.

[3]  S. Engel,et al.  Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo‐controlled randomized study , 2017, Diabetes, obesity & metabolism.

[4]  A. Giaccari,et al.  Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date , 2017, Drug design, development and therapy.

[5]  M. Davies,et al.  Phase III, efficacy and safety study of ertugliflozin monotherapy in people with type 2 diabetes mellitus inadequately controlled with diet and exercise alone , 2017, Diabetes, obesity & metabolism.

[6]  J. Garber,et al.  CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[7]  Vikram Singh,et al.  Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review , 2016, Advances in Therapy.

[8]  R. Vettor,et al.  SGLT2 Inhibitors and the Diabetic Kidney , 2016, Diabetes Care.

[9]  John M Lachin,et al.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.

[10]  Irl B Hirsch,et al.  CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2016 EXECUTIVE SUMMARY. , 2016, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[11]  M. Korytkowski.  Section 9: Pharmacologic Approaches to Glycemic Treatment , 2024, Clinical diabetes : a publication of the American Diabetes Association.

[12]  G. Nucci,et al.  Blood pressure‐lowering effect of the sodium glucose co‐transporter‐2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension , 2015, Diabetes, obesity & metabolism.

[13]  G. Nucci,et al.  Dose‐ranging efficacy and safety study of ertugliflozin, a sodium‐glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin , 2015, Diabetes, obesity & metabolism.

[14]  T. Orchard,et al.  Use of an Electronic Medical Record (EMR) to Identify Glycemic Intensification Strategies in Type 2 Diabetes , 2015, Journal of diabetes science and technology.

[15]  R. DeFronzo,et al.  Initial Combination of Empagliflozin and Linagliptin in Subjects With Type 2 Diabetes , 2015, Diabetes Care.

[16]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2014, Diabetes Care.

[17]  U. Broedl,et al.  Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus , 2014, Circulation.

[18]  R. DeFronzo,et al.  Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. , 2014, The Journal of clinical investigation.

[19]  T. Heise,et al.  Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. , 2014, The Journal of clinical investigation.

[20]  A. Scheen.  Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus , 2014, Drugs.

[21]  K. Khunti,et al.  Clinical Inertia in People With Type 2 Diabetes , 2013, Diabetes Care.

[22]  J. Saaddine,et al.  Achievement of goals in U.S. diabetes care, 1999-2010. , 2013, The New England journal of medicine.

[23]  V. Woo,et al.  Pharmacologic management of type 2 diabetes. , 2013, Canadian journal of diabetes.

[24]  K. Khunti,et al.  A retrospective cohort study of more than 80,000 people , 2013 .

[25]  B. Goldstein,et al.  A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents , 2011, Diabetes, obesity & metabolism.

[26]  M. Davies,et al.  Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy , 2011, Diabetes, obesity & metabolism.

[27]  Executive Summary: Standards of Medical Care in Diabetes—2009 , 2009, Diabetes Care.

[28]  M. Davies,et al.  Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes * , 2008, Diabetes, obesity & metabolism.

[29]  A. Karasik,et al.  Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. , 2008, Current medical research and opinion.

[30]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[31]  M. Hanefeld,et al.  Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus , 2006, Diabetologia.

[32]  A. Tura,et al.  Insulinogenic indices from insulin and C-peptide: comparison of beta-cell function from OGTT and IVGTT. , 2006, Diabetes research and clinical practice.

[33]  N. Clark,et al.  Standards of Medical Care in Diabetes: Response to Power , 2006 .

[34]  S. Inzucchi.  Oral antihyperglycemic therapy for type 2 diabetes: scientific review. , 2002, JAMA.

[35]  M Nurminen,et al.  Comparative analysis of two rates. , 1985, Statistics in medicine.